Random prospective study of cyclophosphamide, doxorubicin, and methotrexate (CAM) combination chemotherapy versus single-agent sequential chemotherapy in non-small cell lung cancer

Lawrence Einhorn, S. D. Williams, E. E. Stevens, W. H. Bond, L. Chenoweth

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

A group of 101 patients with unresectable non-small cell lung cancer were randomized to receive combination chemotherapy with cyclophosphamide, doxorubicin, and methotrexate (CAM) or single-agent chemotherapy with the same three agents. CAM combination chemotherapy produced a 22% objective response rate, including two complete remissions, compared to 9% response rate, including one complete remission, produced by single-agent therapy (P = 0.16). The median survival time was 32 weeks (range, 3-116) for CAM, compared to 25 weeks (range, 4-179+) for sequential single agents (P = 0.24). Overall survival was 31% (1-year), 16% (1 1/2 -year), and 5% (2-year), with no difference between the study arms. Although there was no statistically significant survival advantage for the CAM arm, both arms had survival superior to that in historical controls, presumably because of better patient selection. This study indicates that cyclophosphamide, doxorubicin, and methotrexate are, at best, marginally active as single agents, and new drugs with more efficacy are needed before combination chemotherapy can be expected to result in any meaningful prolongation of survival in non-small cell lung cancer.

Original languageEnglish
Pages (from-to)2005-2011
Number of pages7
JournalCancer Treatment Reports
Volume66
Issue number12
StatePublished - 1982

Fingerprint

Combination Drug Therapy
Methotrexate
Non-Small Cell Lung Carcinoma
Doxorubicin
Cyclophosphamide
Prospective Studies
Drug Therapy
Survival
Patient Selection
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Random prospective study of cyclophosphamide, doxorubicin, and methotrexate (CAM) combination chemotherapy versus single-agent sequential chemotherapy in non-small cell lung cancer. / Einhorn, Lawrence; Williams, S. D.; Stevens, E. E.; Bond, W. H.; Chenoweth, L.

In: Cancer Treatment Reports, Vol. 66, No. 12, 1982, p. 2005-2011.

Research output: Contribution to journalArticle

@article{ec82d7b015834b3dace906eeafdfce30,
title = "Random prospective study of cyclophosphamide, doxorubicin, and methotrexate (CAM) combination chemotherapy versus single-agent sequential chemotherapy in non-small cell lung cancer",
abstract = "A group of 101 patients with unresectable non-small cell lung cancer were randomized to receive combination chemotherapy with cyclophosphamide, doxorubicin, and methotrexate (CAM) or single-agent chemotherapy with the same three agents. CAM combination chemotherapy produced a 22{\%} objective response rate, including two complete remissions, compared to 9{\%} response rate, including one complete remission, produced by single-agent therapy (P = 0.16). The median survival time was 32 weeks (range, 3-116) for CAM, compared to 25 weeks (range, 4-179+) for sequential single agents (P = 0.24). Overall survival was 31{\%} (1-year), 16{\%} (1 1/2 -year), and 5{\%} (2-year), with no difference between the study arms. Although there was no statistically significant survival advantage for the CAM arm, both arms had survival superior to that in historical controls, presumably because of better patient selection. This study indicates that cyclophosphamide, doxorubicin, and methotrexate are, at best, marginally active as single agents, and new drugs with more efficacy are needed before combination chemotherapy can be expected to result in any meaningful prolongation of survival in non-small cell lung cancer.",
author = "Lawrence Einhorn and Williams, {S. D.} and Stevens, {E. E.} and Bond, {W. H.} and L. Chenoweth",
year = "1982",
language = "English",
volume = "66",
pages = "2005--2011",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Random prospective study of cyclophosphamide, doxorubicin, and methotrexate (CAM) combination chemotherapy versus single-agent sequential chemotherapy in non-small cell lung cancer

AU - Einhorn, Lawrence

AU - Williams, S. D.

AU - Stevens, E. E.

AU - Bond, W. H.

AU - Chenoweth, L.

PY - 1982

Y1 - 1982

N2 - A group of 101 patients with unresectable non-small cell lung cancer were randomized to receive combination chemotherapy with cyclophosphamide, doxorubicin, and methotrexate (CAM) or single-agent chemotherapy with the same three agents. CAM combination chemotherapy produced a 22% objective response rate, including two complete remissions, compared to 9% response rate, including one complete remission, produced by single-agent therapy (P = 0.16). The median survival time was 32 weeks (range, 3-116) for CAM, compared to 25 weeks (range, 4-179+) for sequential single agents (P = 0.24). Overall survival was 31% (1-year), 16% (1 1/2 -year), and 5% (2-year), with no difference between the study arms. Although there was no statistically significant survival advantage for the CAM arm, both arms had survival superior to that in historical controls, presumably because of better patient selection. This study indicates that cyclophosphamide, doxorubicin, and methotrexate are, at best, marginally active as single agents, and new drugs with more efficacy are needed before combination chemotherapy can be expected to result in any meaningful prolongation of survival in non-small cell lung cancer.

AB - A group of 101 patients with unresectable non-small cell lung cancer were randomized to receive combination chemotherapy with cyclophosphamide, doxorubicin, and methotrexate (CAM) or single-agent chemotherapy with the same three agents. CAM combination chemotherapy produced a 22% objective response rate, including two complete remissions, compared to 9% response rate, including one complete remission, produced by single-agent therapy (P = 0.16). The median survival time was 32 weeks (range, 3-116) for CAM, compared to 25 weeks (range, 4-179+) for sequential single agents (P = 0.24). Overall survival was 31% (1-year), 16% (1 1/2 -year), and 5% (2-year), with no difference between the study arms. Although there was no statistically significant survival advantage for the CAM arm, both arms had survival superior to that in historical controls, presumably because of better patient selection. This study indicates that cyclophosphamide, doxorubicin, and methotrexate are, at best, marginally active as single agents, and new drugs with more efficacy are needed before combination chemotherapy can be expected to result in any meaningful prolongation of survival in non-small cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0020371718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020371718&partnerID=8YFLogxK

M3 - Article

C2 - 6291763

AN - SCOPUS:0020371718

VL - 66

SP - 2005

EP - 2011

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 12

ER -